145 related articles for article (PubMed ID: 17624989)
1. Mucinous ovarian cancer.
Harrison ML; Jameson C; Gore ME
Int J Gynecol Cancer; 2008; 18(2):209-14. PubMed ID: 17624989
[TBL] [Abstract][Full Text] [Related]
2. Mucinous epithelial ovarian carcinoma.
Perren TJ
Ann Oncol; 2016 Apr; 27 Suppl 1():i53-i57. PubMed ID: 27141073
[TBL] [Abstract][Full Text] [Related]
3. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.
Hess V; A'Hern R; Nasiri N; King DM; Blake PR; Barton DP; Shepherd JH; Ind T; Bridges J; Harrington K; Kaye SB; Gore ME
J Clin Oncol; 2004 Mar; 22(6):1040-4. PubMed ID: 15020606
[TBL] [Abstract][Full Text] [Related]
4. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
5. Mucinous tumours of the ovary.
Naik JD; Seligmann J; Perren TJ
J Clin Pathol; 2012 Jul; 65(7):580-4. PubMed ID: 22011449
[TBL] [Abstract][Full Text] [Related]
6. Unmasking the complexities of mucinous ovarian carcinoma.
Frumovitz M; Schmeler KM; Malpica A; Sood AK; Gershenson DM
Gynecol Oncol; 2010 Jun; 117(3):491-6. PubMed ID: 20332054
[TBL] [Abstract][Full Text] [Related]
7. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
[TBL] [Abstract][Full Text] [Related]
8. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
Vang R; Gown AM; Zhao C; Barry TS; Isacson C; Richardson MS; Ronnett BM
Am J Surg Pathol; 2007 Jun; 31(6):854-69. PubMed ID: 17527072
[TBL] [Abstract][Full Text] [Related]
9. Early stage mucinous ovarian cancer: A review.
Crane EK; Brown J
Gynecol Oncol; 2018 Jun; 149(3):598-604. PubMed ID: 29429591
[TBL] [Abstract][Full Text] [Related]
10. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D; Usubutun A
Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
[TBL] [Abstract][Full Text] [Related]
11. Mucinous tumors of the ovary: current thoughts on diagnosis and management.
Brown J; Frumovitz M
Curr Oncol Rep; 2014 Jun; 16(6):389. PubMed ID: 24777667
[TBL] [Abstract][Full Text] [Related]
12. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma.
Kelemen LE; Köbel M
Lancet Oncol; 2011 Oct; 12(11):1071-80. PubMed ID: 21616717
[TBL] [Abstract][Full Text] [Related]
13. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
14. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
[TBL] [Abstract][Full Text] [Related]
15. Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma.
Ledermann JA; Luvero D; Shafer A; O'Connor D; Mangili G; Friedlander M; Pfisterer J; Mirza MR; Kim JW; Alexandre J; Oza A; Brown J
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S14-9. PubMed ID: 25341574
[TBL] [Abstract][Full Text] [Related]
16. Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors.
Dolivet E; Gaichies L; Jeanne C; Bazille C; Briand M; Vernon M; Giffard F; Leprêtre F; Poulain L; Denoyelle C; Vigneron N; Fauvet R
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958997
[TBL] [Abstract][Full Text] [Related]
17. III. Ovarian cancer 2. Treatment strategy for mucinous adenocarcinoma of the ovary.
Gan To Kagaku Ryoho; 2012 Feb; 39(2):202-205. PubMed ID: 22545288
[No Abstract] [Full Text] [Related]
18. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
19. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas.
Feltmate CM; Lee KR; Johnson M; Schorge JO; Wong KK; Hao K; Welch WR; Bell DA; Berkowitz RS; Mok SC
Clin Cancer Res; 2005 Nov; 11(21):7651-7. PubMed ID: 16278384
[TBL] [Abstract][Full Text] [Related]
20. Rare epithelial tumors arising in or near the ovary: a review of the risk factors, presentation, and future treatment direction for ovarian clear cell and mucinous carcinoma.
Jain A; Seiden MV
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
